Lurbinectedin is a chemotherapeutic DNA alkylating agent used in the treatment of metastatic small-cell lung cancer. It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate Ecteinascidia turbinata, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline...
- Mechanism
- Curator reviewed · 5 references
Lurbinectedin is a DNA alkylating agent. It covalently binds to guanine residues in the DNA minor groove, forming adducts that bend the DNA helix towards the major groove. This process triggers a cascade of events that affect the activity of transcription factors and impairs DNA repair pathways, ultimately leading to double-strand DNA breaks and eventual cell death. Additional mechanism(s) of action include inhibition of RNA-polymerase-II activity, inactivation of Ewing Sarcoma Oncoprotein (EWS-FL11) via nuclear redistribution, and the inhibition of human monocyte activity and macrophage infiltration into tumor tissue.
- Primary indication
- Lurbinectedin is indicated for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.Curator reviewed · 3 structured indications
- Formula / weight
- C41H44N4O10S · 784.88 g/mol (avg)
- First approval
- Canada, 2021 · United States, 2020
- Code names
- JZP712 · PM-01183 · PM1183 · WHO 9397
- Brand names
Resolves to
YDDMIZRDDREKEP-HWTBNCOESA-NSMILES[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4NC4=CC=C(OC)C=C54)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@@]2([H])N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31What you can answer from here — as of August 31, 2026
Which other approved drugs treat the same conditions as Lurbinectedin, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account